Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Clinical Trial for CTD-ILD Treatment (ENACT)

This study has been terminated.
(Departure of study team)
Information provided by (Responsible Party):
Kristine Phillips, University of Michigan Identifier:
First received: August 24, 2011
Last updated: January 14, 2016
Last verified: January 2016
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).

Condition Intervention Phase
Interstitial Lung Disease
Connective Tissue Disease
Drug: N-Acetylcysteine
Phase 2
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Trial of Oral Medication for CTD-ILD Treatment

Resource links provided by NLM:

Further study details as provided by University of Michigan:

Primary Outcome Measures:
  • Pulmonary Function Tests [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]

Enrollment: 5
Study Start Date: December 2011
Estimated Study Completion Date: February 2018
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: N-Acetylcysteine
This is an open label trial, all patient will be entered into one treatment arm.
Drug: N-Acetylcysteine
600mg by mouth, three times daily for 12 months
Other Names:
  • NAC
  • acetylcysteine

Detailed Description:
The investigators will assess tolerability and safety at scheduled intervals via standard of care physical exam findings, monitoring complete blood count, serum chemistry, and pulmonary function tests, along with patient reports of medication intolerance and change in symptoms of dyspnea.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  1. Subject gives voluntary written informed consent to participate in the study.
  2. Subject has been diagnosed with a connective tissue disease and associated interstitial lung disease confirmed by computed tomography of the lungs along with symptoms of cough and/or shortness of breath.
  3. Males and females age greater than 18 years at time of screening.
  4. Females of childbearing potential must be willing to use a reliable form of medically acceptable contraception and have a negative pregnancy test confirmed at baseline before starting NAC as per standard of care. Women who are surgically sterile or have been post-menopausal for at least two years are not considered to be of child-bearing potential.


  1. History of severe chronic kidney disease defined as a glomerular filtration rate of less than 30.
  2. Hemoglobin concentration less than 70% of the lower limit of the normal range at time of screening.
  3. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01424033

United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan
Study Director: Kristine Phillips, MD University of Michigan
  More Information

Responsible Party: Kristine Phillips, M.D., University of Michigan Identifier: NCT01424033     History of Changes
Other Study ID Numbers: HUM00049434 
Study First Received: August 24, 2011
Results First Received: January 14, 2016
Last Updated: January 14, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Michigan:
Interstitial lung disease
Connective tissue disease
Rheumatoid arthritis
Sjogren's syndrome
Mixed connective tissue disease
Systemic lupus erythematosis

Additional relevant MeSH terms:
Lung Diseases
Connective Tissue Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases
Antiviral Agents
Anti-Infective Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes processed this record on October 25, 2016